SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Novel Apolipoprotein A-I Therapy, CSL Limited112, May Represent New Option for Reducing Recurrent Heart Attack Risk, Early CSL Studies Show